ANIK - Anika Therapeutics, Inc.
IEX Last Trade
16.24
0.050 0.308%
Share volume: 357
Last Updated: Fri 27 Dec 2024 08:28:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$16.19
0.05
0.31%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-09 | 2023-03-16 | 2023-05-09 | 2023-08-08 | 2023-11-03 | 2024-03-15 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 354.123 M | 347.746 M | 349.128 M | 339.074 M | 328.882 M | 328.158 M | 270.632 M | 263.744 M | |
| Current Assets | 167.856 M | 167.761 M | 169.547 M | 160.331 M | 152.201 M | 156.778 M | 163.309 M | 158.962 M | |
| Inventories | 35.336 M | 37.237 M | 39.765 M | 41.319 M | 42.604 M | 43.724 M | 46.386 M | 49.408 M | |
| Other Current Assets | 8.956 M | 8.579 M | 8.828 M | 8.646 M | 7.789 M | 7.721 M | 8.095 M | 8.848 M | |
| Short Term Investments | 8.956 M | 8.579 M | 8.828 M | 8.646 M | 7.789 M | 7.721 M | 8.095 M | 8.848 M | |
| Total Receivables | 32.172 M | 34.168 M | 34.627 M | 30.629 M | 36.737 M | 34.682 M | 35.961 M | 32.077 M | |
| Current Cash | 91.392 M | 87.777 M | 86.327 M | 79.737 M | 65.071 M | 70.651 M | 72.867 M | 68.629 M | |
| Total Non-current Assets | 186.267 M | 179.985 M | 179.581 M | 178.743 M | 176.681 M | 171.380 M | 107.323 M | 104.782 M | |
| Property Plant Equipment | 48.087 M | 47.390 M | 48.279 M | 48.803 M | 47.988 M | 45.937 M | 46.198 M | 46.057 M | |
| Other Assets | 20.914 M | 18.342 M | 17.219 M | 18.131 M | 19.390 M | 18.951 M | 18.672 M | 17.571 M | |
| Intangible Assets | 78.490 M | 76.545 M | 74.599 M | 72.653 M | 70.707 M | 68.762 M | 4.626 M | 4.297 M | |
| Goodwill | 7.169 M | 6.721 M | 7.339 M | 7.462 M | 7.467 M | 7.253 M | 7.571 M | 7.403 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 354.123 M | 347.746 M | 349.128 M | 339.074 M | 328.882 M | 328.158 M | 270.632 M | 263.744 M | |
| Total liabilities | 67.970 M | 62.809 M | 63.565 M | 61.486 M | 54.867 M | 57.672 M | 58.367 M | 55.208 M | |
| Total current liabilities | 29.431 M | 26.352 M | 27.914 M | 28.693 M | 23.456 M | 28.064 M | 31.059 M | 28.460 M | |
| Accounts Payable | 8.165 M | 8.353 M | 9.074 M | 8.948 M | 7.944 M | 8.251 M | 9.860 M | 10.022 M | |
| Other liabilities | 587.000 K | 474.000 K | 398.000 K | 399.000 K | 401.000 K | 400.000 K | 404.000 K | 404.000 K | |
| Current long term debt | 132.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 587.000 K | 474.000 K | 398.000 K | 399.000 K | 401.000 K | 400.000 K | 404.000 K | 404.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 286.153 M | 284.937 M | 285.563 M | 277.588 M | 274.015 M | 270.486 M | 212.265 M | 208.536 M | |
| Common stock | 14.555 M | 14.603 M | 14.620 M | 14.653 M | 14.688 M | 14.635 M | 14.648 M | 14.698 M | |
| Retained earnings | 219.802 M | 215.627 M | 210.719 M | 200.369 M | 197.628 M | 191.052 M | 128.052 M | 123.538 M |